Management of Early-Stage Resected Non-Small Cell Lung Cancer: Consensus Statement of the Lung cancer Consortium

Cancer Treat Res Commun. 2022:31:100538. doi: 10.1016/j.ctarc.2022.100538. Epub 2022 Feb 22.

Abstract

Background: Management of early-stage non-small cell lung cancer (ES-NSCLC) has evolved over the last few years especially in terms of work-up and the use of systemic therapy. This consensus statement was developed to present updated guidelines for the management of this disease.

Methods: Multidisciplinary team (MDT) of lung cancer experts convened to discuss a set of pertinent questions with importance relevance to the management of ES-NSCLC. ES-NSCLC includes stages I, II and resected stage III. The experts included consultants in chest imaging, thoracic surgery, radiation oncology, and medical oncology. Questions were discussed in virtual meetings and then a written manuscript with supporting evidence was drafted, reviewed, and approved by the team members.

Results: The Consensus Statement included 9 questions addressing work-up and management of ES-NSCLC. Background information and literature review were presented for each question followed by specific recommendations to address the questions by oncology providers. The Statement was endorsed by various oncology societies in the Gulf region.

Conclusion: The Consensus Statement serves as a guide for thoracic MDT members in the management of ES-NSCLC. Adaptation of these to the local setting is dictated usually by available resources and expertise, however, all efforts should be excreted to provide the optimal care to all patients whenever possible.

Keywords: Early Stage; Guidelines; Management; Non-small cell lung cancer.

Publication types

  • Review

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / surgery
  • Consensus
  • Humans
  • Lung Neoplasms* / surgery
  • Medical Oncology
  • Small Cell Lung Carcinoma*